Bio Green Med Solution, Inc.(BGMS)

Medical - Pharmaceuticals · Kuala Lumpur, LF

$0.90+0.03 (+3.52%)

Delayed quote: Oct 6, 2026, 10:07 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T14:15:53.934Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:15:53.934Z.

Quote observation: 2026-10-06T14:07:51.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,961,990
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 3,790,000
TTM free cash flow · period ending 2026-06-30: -1,098,000

FMP input reference: c636d25f821ca328dde5756eba65a9b4f657646c0770229dc3782e5e279f5fe4

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BGMS EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

BGMS Competitors' EV/FCF Ratio

BGMS

Bio Green Med Solution, Inc.

Current

Market Cap

$4.96M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GELS

Gelteq Limited Ordinary Shares

vs BGMS

Market Cap

$5.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs BGMS

Market Cap

$4.83M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs BGMS

Market Cap

$4.74M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs BGMS

Market Cap

$5.21M

EV/FCF Ratio

N/A

TTM Avg

11.91x

3Y Avg

14.69x

5Y Avg

14.69x

ALZN

Alzamend Neuro Inc

vs BGMS

Market Cap

$5.33M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LNAI

Lunai Bioworks Inc.

vs BGMS

Market Cap

$5.35M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LIMN

Liminatus Pharma, Inc. Class A Common Stock

vs BGMS

Market Cap

$5.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRMA

Dermata Therapeutics, Inc.

vs BGMS

Market Cap

$4.50M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMGL

Basel Medical Group Ltd Ordinary Shares

vs BGMS

Market Cap

$5.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Bio Green Med Solution, Inc. (BGMS)	$4.96M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$5.10M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.83M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.74M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.21M	N/A	11.91x	14.69x	14.69x
Alzamend Neuro Inc (ALZN)vs ›	$5.33M	N/A	N/A	N/A	N/A
Lunai Bioworks Inc. (LNAI)vs ›	$5.35M	N/A	N/A	N/A	N/A
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.10M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.50M	N/A	N/A	N/A	N/A
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.29M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

BGMS EV/FCF Ratio Metrics

BGMS Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics